Adma Biologics (ADMA) Total Non-Current Liabilities (2011 - 2025)

Adma Biologics has reported Total Non-Current Liabilities for 14 years, with the latest figure at $146.9 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities rose 5.47% year-over-year to $146.9 million; the trailing twelve-month figure through Dec 2025 stood at $146.9 million (up 5.47% YoY), and the FY2025 full-year result was $146.9 million, up 5.47% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $146.9 million, up from $137.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $199.8 million in Q3 2022, with the low at $121.2 million in Q2 2021.
• Historically, Total Non-Current Liabilities has averaged $165.9 million across 5 years, with a median of $170.4 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 50.32% — and 2025, when it slumped 30.3%.
• Adma Biologics' Total Non-Current Liabilities stood at $134.7 million in 2021, then surged by 45.63% to $196.1 million in 2022, then declined by 1.32% to $193.6 million in 2023, then slipped by 28.03% to $139.3 million in 2024, then rose by 5.47% to $146.9 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $146.9 million (Q4 2025), $137.4 million (Q3 2025), and $160.1 million (Q2 2025), per Business Quant data.